In this issue:
Dapagliflozin in HF with mildly reduced/preserved EF: HF events
AF ablation for HFPEF
Uptitrating treatment after HF hospitalisation across LVEF spectrum
ARNI for mildly reduced/preserved EF and worsening HF
HF hospitalisations with tablet-based telemonitoring added to phone management
SGLT-2 inhibitors vs. sitagliptin in HF and type 2 diabetes
Importance of cystatin C in estimating GFR
Skeletal muscle mitochondrial respiration and exercise intolerance in HFPEF
Autonomic regulation therapy in chronic HF with preserved/mildly reduced EF
HF care quality and outcomes at US hospitals with high proportions of Black patients
Please login below to download this issue (PDF)